- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 2153
10-year publication summary
|
122
|
145
|
163
|
176
|
159
|
229
|
251
|
199
|
159
|
106
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 358 |
143 |
| Regeneron Pharmaceuticals, Inc. | 4261 |
129 |
| Amgen Inc. | 4049 |
35 |
| The Regents of the University of California | 19943 |
31 |
| Immatics Biotechnologies GmbH | 1157 |
31 |
| Keros Therapeutics, Inc. | 64 |
25 |
| Board of Regents, The University of Texas System | 5798 |
22 |
| The Board of Trustees of the Leland Stanford Junior University | 6424 |
21 |
| Genentech, Inc. | 3983 |
20 |
| The Trustees of the University of Pennsylvania | 4329 |
20 |
| City of Hope | 994 |
20 |
| Immunitybio, Inc. | 373 |
20 |
| Genzyme Corporation | 1263 |
18 |
| The Johns Hopkins University | 5671 |
16 |
| Biocon Limited | 221 |
16 |
| Precigen Inc | 117 |
16 |
| Novartis AG | 10829 |
15 |
| Merck Patent GmbH | 5818 |
15 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3367 |
15 |
| National Research Council of Canada | 1550 |
14 |
| Other owners | 1511 |